Veopoz

Active Ingredient(s): Pozelimab-bbfg
FDA Approved: * August 18, 2023
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Genetic Disorders
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Veopoz 200 mg/ml Intravenous; Subcutaneous Injection, Solution
NDC: 61755-014
Labeler:
Regeneron Pharmaceuticals, Inc.